Skip to main content
. 2016 May 6;100(4):699–709. doi: 10.1189/jlb.1A0914-425RR

Figure 1. A cAMP analog inhibits chemotaxis to multiple chemokines.

Figure 1.

Purified CD4+ T cells from naïve mice were examined for their capacity to chemotax through a Transwell insert toward an optimal concentration (100 ng/ml) of CXCL12 (A) or an optimal (100 ng/ml; B) or suboptimal (25 ng/ml; C and D) and (E) concentration of CCL21 following pretreatment with various doses of the cAMP analog cBiMPS. (A and C) One group of cells was pretreated with the PKA inhibitor Rp-cAMPS to determine the role of PKA in the observed chemotaxis inhibition. (D) All cells were pretreated with the Epac inhibitor ESI-09 and then treated with 50 μM cBiMPS or left untreated. (E) One group of cells was pretreated with the Epac agonist 8-pCPT-2′-O-Me-cAMP. (A–C) Means ± sd represent 6 separate experiments, each using T cells pooled from ≥3 mice. (D and E) Means ± sd represent 4 separate experiments, each using T cells pooled from ≥4 mice. *P < 0.5.